<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and prevention of infections associated with biologic agents and JAK inhibitors in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and prevention of infections associated with biologic agents and JAK inhibitors in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and prevention of infections associated with biologic agents and JAK inhibitors in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Conrad Liles, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua A Hill, MD, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin L Winthrop, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H847138035"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Biologic agents are a rapidly expanding therapeutic strategy for a wide range of medical conditions. These targeted approaches have improved outcomes for many chronic diseases but, at the same time, induce unique immunologic deficits that may increase the risk for common and opportunistic infections.</p><p>This topic provides an overview of the various classes of biologic agents along with janus kinase (JAK) inhibitors, their associated infections, and approaches to mitigate risk. The number of biologic agents is constantly expanding; the more commonly used nononcologic biologic agents are discussed here.</p><p>A more detailed overview of the mechanism of action and the secondary immunodeficiency caused by many of these agents is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H545186372"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H218788576"><span class="h2">Immunologic mechanisms</span><span class="headingEndMark"> — </span>Biologic agents are designed to interfere with the biological activity of a component of the immune system, typically a cytokine or a cellular receptor. Cytokines are soluble proteins that interact with immune cells to control proinflammatory responses, cellular activation, and cell migration. Cell receptors reside on the surface of immune cells and can initiate cellular activation or drive cell migration upon recognizing their respective cognate ligand. By interfering with the normal activities of these molecules, biologic agents disrupt signaling pathways that drive activation and migration of immune cells to sites of infection, thereby interfering with the host immune response and increasing risk for infection.</p><p>Many biologic therapies are associated with an increased risk of opportunistic infections. As an example, in a meta-analysis of 70 randomized controlled trials that included over 32,000 patients with rheumatoid arthritis, use of a biologic agent (tumor necrosis factor [TNF]-alpha inhibitors, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) was associated with higher incidence of opportunistic infections compared with placebo (odds ratio [OR] 1.79, 95% CI 1.17-2.74; one additional opportunistic infection for every 582 patients treated with a biologic agent) [<a href="#rid1">1</a>]. Consequently, we test and/or vaccinate for certain latent and/or chronic infections prior to the start of these biologic agents.</p><p class="headingAnchor" id="H4202724004"><span class="h2">Pretreatment infectious testing</span><span class="headingEndMark"> — </span>Biologic agents can increase the risk for serious and potentially fatal infections from bacteria, viruses, fungi, and occasionally parasites [<a href="#rid1">1-5</a>]. The risk varies depending on the type of immunosuppressive agent, the condition being treated, and the concomitant use of other immunosuppressants (eg, corticosteroids). For some conditions, there may be additional infectious testing necessary (eg, cytomegalovirus [CMV] in select cases of ulcerative colitis) for diagnostic purposes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline testing</strong> – Baseline testing for some latent infections is recommended prior to initiating therapy with many of the medications in this section. In general, most of the biologic agents discussed here warrant testing for the following infections:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis infection (TBI), previously known as latent tuberculosis infection  (<a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef118038" href="/z/d/graphic/118038.html" rel="external">algorithm 2</a>) (see  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV)  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>) (see  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults", section on 'Approach to screening and testing'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis C virus (HCV)  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a>) (see  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>)</p><p></p><p class="bulletIndent1">For patients who do not have a negative human immunodeficiency virus (HIV) test documented in their records or are at increased risk of acquiring HIV (eg, men who have sex with men, engagement in sex work), the pretreatment infectious testing process is a good opportunity to provide routine HIV screening prior to the initiation of immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Preferred approach'</a>.)</p><p></p><p class="bulletIndent1">Specific testing recommendations for each biologic agent are discussed in the corresponding sections below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of identified infections</strong> – If any infections are discovered on pretreatment testing, we treat the underlying infection and hold off on starting the biologic agent until the infection is controlled, if possible. Close monitoring is paramount to make sure there is no worsening of the underlying infection once the biologic agent is started.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tuberculosis infection</strong> – Those who test positive for TBI warrant tuberculosis (TB) treatment prior to initiating the biologic agent. (See  <a class="medical medical_review" href="/z/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis B</strong> – Those who test positive for chronic HBV infection may require antiviral prophylaxis to prevent HBV reactivation while they are on the biologic agent. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H1911727558"><span class="h2">Timing of vaccinations</span></p><p class="headingAnchor" id="H2704655555"><span class="h3">Prior to initiating biologics</span><span class="headingEndMark"> — </span>We make sure that all patients initiating biologics have age-appropriate routine vaccinations (including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] vaccine series and annual influenza vaccination, if applicable) completed prior to starting therapy when feasible, because some vaccinations may be less effective during and after therapy or may be contraindicated (eg, live vaccines)  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a>) [<a href="#rid6">6-9</a>]. Routine vaccinations should be administered at least two weeks before starting these immunomodulatory therapies if possible, and timing should be extended to at least four weeks for live vaccines  (<a class="graphic graphic_table graphicRef112956" href="/z/d/graphic/112956.html" rel="external">table 2</a>) [<a href="#rid10">10,11</a>]. Although concrete efficacy data are limited, therapeutic agents that target down-regulation of immune responses (eg, antigen presenting cells [dendritic cells and macrophages], T cells, and B cells) could potentially impair the immunogenicity and/or effectiveness of newly administered vaccines.</p><p>Additional recommended vaccinations for some biologic agents may include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcal vaccination</strong> (see  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults", section on 'Pneumococcal vaccines'</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Approach to vaccination'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella/herpes zoster vaccination</strong> – Generally, assessing for prior varicella zoster virus (VZV) infection by history and/or medical records is sufficient to document prior exposure to VZV. If a patient has been exposed to VZV (either by vaccination or by natural infection), we administer the nonlive <a class="drug drug_general" data-topicid="115351" href="/z/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a> (RZV) to adult patients at least two weeks prior to initiating immunosuppressive therapy. </p><p></p><p class="bulletIndent1">If a patient has never been exposed to varicella, some experts administer the live VZV vaccine, barring any contraindications, with the goal to complete the whole series at least four weeks prior to initiating immunosuppressive therapy, while others administer RZV irrespective of prior exposure history. (See  <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)", section on 'Immunocompromised persons'</a> and  <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Immunocompromised hosts'</a>.)</p><p></p><p class="headingAnchor" id="H2218465433"><span class="h3">During treatment with biologics</span><span class="headingEndMark"> — </span>Vaccination with nonlive vaccines during therapy may be considered if the benefit of vaccination outweighs the risk (eg, annual influenza vaccination) [<a href="#rid12">12,13</a>]. Although vaccine efficacy may be attenuated, the humoral response often remains intact, and some protective antibody levels can be achieved.</p><p>When possible, vaccination should be given at the nadir of immunosuppression. This is often achieved by administering the nonlive vaccine midcycle of each dose interval (eg, at two weeks for a four-week dose interval). In general, we do not hold back treatments required for managing the associated chronic medical condition in order to optimize immune responses. However, with some treatments, such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, one can consider temporary discontinuation of the drug [<a href="#rid9">9</a>]. If treatment is discontinued, the length of time should be guided by the drug's pharmacokinetics and the expected time to immune recovery, as there are limited real-world data to provide specific guidance for this practice for any given drug.</p><p>Live vaccinations are typically contraindicated while receiving biologic agents. Specific vaccination recommendations for each biologic agent are discussed in the corresponding sections below.</p><p>Further detailed discussion of vaccine administration timing while the patient is taking immunosuppressive therapy for rheumatic diseases is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p class="headingAnchor" id="H1761567072"><span class="h2">Active infections during treatment</span><span class="headingEndMark"> — </span>In the event of a new serious infection while on treatment, the biologic agent should be stopped while the infection is treated [<a href="#rid14">14</a>]. Therapy can resume after the active infection is controlled, with close monitoring. If active <em>M. tuberculosis</em> infection is diagnosed during therapy, many of the drugs discussed in this section should be discontinued while treatment is initiated [<a href="#rid15">15-21</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Management'</a>.)</p><p class="headingAnchor" id="H348226777"><span class="h2">Differentiating symptoms of infection versus medication adverse effects</span><span class="headingEndMark"> — </span>Often, it may be difficult to distinguish symptoms of infection from symptoms caused by adverse effects of the biologic agent [<a href="#rid22">22</a>]. Since many drugs discussed here predispose a patient to infections, it is important to complete a comprehensive evaluation for infection prior to attributing the patient's symptoms to the medication.</p><p class="headingAnchor" id="H510729264"><span class="h1">TUMOR NECROSIS FACTOR (TNF)-ALPHA INHIBITORS (TNFI)</span><span class="headingEndMark"> — </span>TNF is a pleiotropic cytokine that is an important component of innate immunity. TNF receptor binding leads to the release of proinflammatory cytokines, chemokines, and adhesion factors. The primary TNFi that have been US Food and Drug Administration (FDA)-approved are monoclonal antibodies (mAbs; eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, certolizumab, and <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>) and engineered antibody fragments (<a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>), which function by binding and inhibiting soluble and membrane-bound TNF. <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a> is a fusion protein that acts as a soluble TNF receptor to bind TNF. TNFi therapies disrupt the immune system's capacity to clear intracellular pathogens and those sequestered in granulomas. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'TNF inhibition'</a> and  <a class="medical medical_review" href="/z/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Treatment with TNFi predisposes individuals to the following infections  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>) [<a href="#rid23">23-29</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span><em>Listeria monocytogenes</em>, <em>Nocardia</em> spp, and <em>Legionella</em> spp</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes zoster virus </p><p class="bulletIndent2"><span class="glyph">•</span>Endemic mycoses</p><p class="bulletIndent2"><span class="glyph">•</span>Candidal infections</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection</p><p class="bulletIndent2"><span class="glyph">•</span>Aspergillosis</p><p class="bulletIndent2"><span class="glyph">•</span>Toxoplasmosis (rare)</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis)</p><p></p><p class="bulletIndent1">TNFi particularly predispose an individual to acquisition and/or reactivation of mycobacterial infections (including TB), hepatitis B, and endemic mycoses such as histoplasmosis. Detailed discussions of the risk of infections seen with TNFi are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test patients initiating TNF inhibitors for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>). In regions endemic to specific mycoses, we obtain history of symptoms that would suggest active or recent infection in the past two years and inquire about potential exposures. In patients with risk factors of being exposed to histoplasmosis in the last two years, we obtain a chest radiograph (see  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Histoplasmosis'</a>). In coccidioidomycosis endemic regions, we obtain coccidioides serology to test for previous exposure to <em>Coccidioides</em> spp. (See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Patients receiving immunomodulatory agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for individuals starting TNFi, as discussed above  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>) (see <a class="local">'Timing of vaccinations'</a> above). Vaccine responses may be attenuated while on therapy.</p><p></p><p class="headingAnchor" id="H3130185096"><span class="h1">ABATACEPT</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> is an anti-T cell therapy that inhibits the costimulatory signal by competitively interacting with CD80/CD86 on antigen-presenting cells, blocking binding to T cell-expressed CD28. This prevents T cell activation and proinflammatory cytokine release. (See  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Although <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> is not thought to be severely immunocompromising, it may predispose individuals to the following infections [<a href="#rid26">26-29</a>]  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Epstein-Barr virus and cytomegalovirus (CMV) infection</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis)</p><p></p><p><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> does not appear to greatly increase the risk of infectious complications in most patients. A 2009 meta-analysis of five trials that included 2945 patients found similar rates of serious infection with abatacept compared with placebo (2.5 versus 1.7 percent) [<a href="#rid30">30</a>]. In another compilation of eight clinical trials of patients with rheumatoid arthritis, there was no difference in the infection rate between patients receiving abatacept versus placebo [<a href="#rid31">31</a>]. However, case reports and small retrospective analyses have demonstrated reactivation of hepatitis B with use of abatacept [<a href="#rid26">26-29</a>]. Using a Medicare database of patients with rheumatoid arthritis who had prior treatment with a biologic agent, the risk of infections in hospitalized patients was significantly higher for tumor necrosis factor-alpha inhibitors (TNFi) and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> compared with subjects receiving abatacept [<a href="#rid32">32</a>]. (See <a class="local">'Tumor necrosis factor (TNF)-alpha inhibitors (TNFi)'</a> above and <a class="local">'Anti-B cell agents'</a> below.)</p><p>The safety of <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> was assessed in several trials [<a href="#rid5">5,33</a>]. Serious infections occurred at an incidence rate of 4.3 per 100 person-years. The most frequent infections were pneumonia, bronchitis, cellulitis, and urinary tract infections. The increased risk of respiratory tract infections mostly occurred in patients with underlying pulmonary disease (eg, chronic obstructive pulmonary disease).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test patients initiating <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> for TBI  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for individuals starting <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, as discussed above  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>) (see <a class="local">'Timing of vaccinations'</a> above). Vaccine responses may be attenuated while on therapy. </p><p></p><p class="headingAnchor" id="H2795695379"><span class="h1">ANTI-B CELL AGENTS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> and other anti-B cell antibodies (eg, <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">ofatumumab</a>) are monoclonal antibodies (mAbs) that bind to the CD20 receptor on B cells [<a href="#rid34">34</a>], resulting in B cell depletion. <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a> confers less risk of infection because it prevents activation of B cells instead of depleting them [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1737816594"><span class="h2">Class-wide risk assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Treatment with anti-B cell agents predisposes individuals to the following infections [<a href="#rid36">36-42</a>]  (<a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) [<a href="#rid43">43,44</a>] and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes zoster virus</p><p class="bulletIndent2"><span class="glyph">•</span>Epstein-Barr virus and cytomegalovirus (CMV) infection </p><p class="bulletIndent2"><span class="glyph">•</span>Severe coronavirus disease 2019 (COVID-19) [<a href="#rid45">45-47</a>] (except <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive multifocal leukoencephalopathy (PML; mostly <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, although has been reported with <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Endemic mycoses</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection</p><p class="bulletIndent2"><span class="glyph">•</span><em>Pneumocystis</em> pneumonia (only <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) [<a href="#rid48">48</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis) [<a href="#rid49">49</a>]</p><p></p><p>Out of all the anti-B cell agents, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is associated with the highest risk of serious infections, while <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a> is associated with the lowest risk for serious infections.</p><p>Risk is highest for hepatitis B reactivation. For patients with evidence of active HBV (positive surface antigen) or inactive HBV (positive core antibody, negative surface antigen), we try to avoid anti-B cell agents when possible. If treatment with an anti-B cell agent is necessary, HBV prophylaxis should be initiated prior to treatment to prevent HBV reactivation (see  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Preventing HBV reactivation'</a>). If HBV reactivation is detected, therapy with the CD20 inhibitor should be stopped temporarily until antiviral therapy is initiated and HBV deoxyribonucleic acid (DNA) and alanine aminotransferase decrease to lower levels. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>Infection with SARS-CoV-2 has been a serious complication for those on anti-CD20 therapies, which increases the risk of COVID-19-related hospitalization and death [<a href="#rid45">45,46</a>]. Patients with SARS-CoV-2 infection should be promptly evaluated for treatment. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'</a>.)</p><p>People with HIV receiving anti-CD20 therapies should be closely monitored and strictly adhere to antiviral therapy; guidelines recommend withholding anti-CD20 therapies in patients with a CD4 cell counts ≤50 cells/microL [<a href="#rid50">50</a>].</p><p>The risk of infection is increased when CD20 inhibitors are used in the context of hematological malignancies [<a href="#rid51">51</a>] or solid organ transplants [<a href="#rid52">52,53</a>] compared with the treatment of autoimmune disorders [<a href="#rid54">54</a>]. There is also a risk of developing hypogammaglobulinemia while taking <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, which can further increase infection risk. (See  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test patients initiating anti-B cell agents for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting anti-B cell agents, as discussed above  (<a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a>) (see <a class="local">'Timing of vaccinations'</a> above). Vaccine responses may be attenuated while on therapy and for 6 to 12 months after cessation of therapy. When administering nonlive attenuated vaccines (with the exception of the annual influenza vaccine) during <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> therapy, one can optimize immunogenicity by administering the vaccine at the time the rituximab dose is due and holding rituximab for at least two weeks after vaccination, if disease activity allows [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H3990576059"><span class="h2">Drug-specific risks</span></p><p class="headingAnchor" id="H1843048201"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is a mAb that binds to the CD20 receptor on B cells [<a href="#rid34">34</a>], resulting in B cell depletion. It also disrupts B and T cell interactions, resulting in impaired cellular immunity and increased risk of viral reactivation [<a href="#rid55">55</a>] (see  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>). Usage in the setting of malignancy is reviewed in other chapters. (See  <a class="medical medical_review" href="/z/d/html/85686.html" rel="external">"Treatment protocols for lymphoma"</a>.)</p><p>Out of all the anti-B cell agents, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is associated with the highest risk of serious infections, especially with HBV reactivation. Some experts choose to initiate <em>Pneumocystis</em> spp prophylaxis in patients taking rituximab monotherapy, although the absolute risk is low (see  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'</a>). PML has been observed in patients taking rituximab, but the absolute risk is quite low [<a href="#rid56">56</a>]. There are no recommendations to test for John Cunningham virus (JCV) antibody prior to initiating rituximab. Rituximab should be discontinued if PML is suspected and/or confirmed.</p><p>In addition to increasing risk of bacterial, viral, and fungal infections, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is also associated with attenuated response to vaccines administered during and after discontinuation of the drug [<a href="#rid57">57</a>]. This phenomenon is due to the prolonged time needed for the repletion of B cells within the body. On average, it typically requires six to nine months after discontinuing rituximab for B cells numbers to return to normal [<a href="#rid48">48</a>]. In a study of 120 patients with different types of vasculitides, B cell recovery occurred over a range of 8 to 44 months [<a href="#rid58">58</a>]. Even after normalization of B cell numbers, vaccine response may be attenuated. In a study of 75 patients who received four injections of rituximab or placebo over one month, titers to vaccines administered 12 months after rituximab therapy were lower in patients who received rituximab versus placebo [<a href="#rid59">59</a>].</p><p>Pre-existing immunity to vaccinations administered previously is not affected by treatment. As an example, in a study of 75 patients with type 1 diabetes treated with four injections of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> or placebo over one month and then followed for 12 months (ie, a period sufficient for B cell recovery), measles, mumps, and rubella titers before rituximab and after were unchanged between the rituximab group and placebo [<a href="#rid59">59</a>].</p><p>Additionally, some degree of transient hypogammaglobulinemia is common and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> can also cause "late-onset" neutropenia, appearing one to five months after the end of therapy, which is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies"</a>.)</p><p class="headingAnchor" id="H3582159849"><span class="h3">Ocrelizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">Ocrelizumab</a> is a humanized monoclonal anti-CD20 antibody therapy that triggers antibody-dependent cellular cytolysis. This will deplete circulating immature and mature B cells, not the CD20-negative plasma cells [<a href="#rid60">60,61</a>].</p><p><a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">Ocrelizumab</a> has been associated with a higher risk of infection in comparison to interferon-beta and placebo for treatment of multiple sclerosis. In phase II trials, ocrelizumab was associated with higher rates of nonserious infections, including upper respiratory tract infections, nasopharyngitis, urinary tract infections, skin infections, and herpesvirus infections [<a href="#rid43">43,49</a>]. Cases of osteomyelitis, urosepsis, cystitis, and pyelonephritis have been reported [<a href="#rid49">49</a>]. Additionally, there is a possible correlation between ocrelizumab administration and more severe COVID-19 outcomes [<a href="#rid47">47</a>]. Opportunistic infections appear relatively infrequently, except for serious HBV infections [<a href="#rid43">43</a>]. At least one case of PML was associated with ocrelizumab monotherapy in a patient without prior immunosuppressive therapy [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2409340218"><span class="h3">Ofatumumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9523" href="/z/d/drug information/9523.html" rel="external">Ofatumumab</a> is a fully human monoclonal anti-CD20 monoclonal antibody, which targets a distinct epitope on the CD20 molecules of B cells and induces apoptosis [<a href="#rid63">63</a>]. Limited information is available from clinical studies on the immune effects of this drug. In one uncontrolled trial of 33 patients with chronic lymphocytic leukemia, 51 percent experienced infections, although most were mild or moderate [<a href="#rid40">40</a>]. Reactivation of hepatitis B has also been reported.</p><p class="headingAnchor" id="H2374578315"><span class="h3">Belimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">Belimumab</a>, a mAb that inhibits B cell activating factor, reduces B cell development and survival [<a href="#rid64">64</a>]. Compared with the other anti-B cell treatments and rheumatic disease immunomodulators, belimumab is less likely to increase the risk for serious infections, because it prevents activation of B cells but does not deplete them [<a href="#rid35">35</a>]. Belimumab treatment does not appear to substantially impact the risk for severe COVID-19 [<a href="#rid65">65</a>] or reduce the immune response to vaccination [<a href="#rid66">66</a>]. A low incidence of PML has been observed in patients taking belimumab [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H2409411946"><span class="h3">Others</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">Obinutuzumab</a> and <a class="drug drug_general" data-topicid="128443" href="/z/d/drug information/128443.html" rel="external">inebilizumab</a> are other anti-B cell agents. Although data on these agents are limited, we expect similar risks for infection compared with other anti-B cell agents and provide the same pretreatment testing and vaccinations for patients initiating these agents as other anti-B cell agents.</p><p class="headingAnchor" id="H1401405369"><span class="h1">JANUS KINASE (JAK) INHIBITORS</span><span class="headingEndMark"> — </span>The JAK-signal transducer and activator of transcription pathway transduces cytokine signaling, making it critical to inflammatory responses [<a href="#rid67">67-69</a>]. The JAK family is comprised of four members: JAK1, JAK2, JAK3, and tyrosine kinase 2. Each cytokine receptor requires a pair of two associated JAKs to signal through the cytokine receptor. These kinases are important for proper immune function and hematopoiesis due to their effect on the signaling of numerous cytokines and growth factors [<a href="#rid70">70</a>]. JAK inhibitors include <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, and filgotinib. (See  <a class="medical medical_review" href="/z/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p class="headingAnchor" id="H1184711565"><span class="h2">Class-wide risk assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> –<strong> </strong>Treatment with JAK inhibitors predisposes individuals to the following infections [<a href="#rid71">71-76</a>]  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) [<a href="#rid77">77,78</a>] and other mycobacterial infections</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) [<a href="#rid79">79</a>] and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes zoster virus</p><p class="bulletIndent2"><span class="glyph">•</span>Epstein-Barr virus and cytomegalovirus (CMV)</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive multifocal leukoencephalopathy (PML)</p><p class="bulletIndent2"><span class="glyph">•</span>Endemic mycoses</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection</p><p class="bulletIndent2"><span class="glyph">•</span><em>Pneumocystis</em> pneumonia</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis) [<a href="#rid68">68,78</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test patients initiating JAK inhibitors for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>). In coccidioidomycosis-endemic regions, we also obtain <em>Coccidioides</em> serology if the individual will be starting <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, based on observational data that this agent predisposes patients to reactivation of previous <em>Coccidioides</em> infection. (See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Patients receiving immunomodulatory agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients initiating JAK inhibitors, as discussed above  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H2489585944"><span class="h2">Drug-specific risks</span></p><p class="headingAnchor" id="H2544246288"><span class="h3">Ruxolitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">Ruxolitinib</a> inhibits JAK1 and JAK2, which disrupts cytokine and growth factor signaling to attenuate immune responses.</p><p>Serious bacterial, viral, and fungal infections have been reported in patients treated with <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, including mycobacterial infections, reactivation of HBV, PML, herpes zoster, and coccidioidomycosis [<a href="#rid69">69,80</a>]. Neutropenia may occur, and patients should be closely monitored during treatment.</p><p class="headingAnchor" id="H468411622"><span class="h3">Baricitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">Baricitinib</a>, like <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, is a JAK1/JAK2 inhibitor that blocks plasmablast, Th1, and Th17 differentiation and innate stimulation of T cells [<a href="#rid81">81</a>].</p><p>Patients receiving <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> most commonly report respiratory infections, bronchitis, and urinary tract infections [<a href="#rid71">71-73</a>]. Herpes zoster occurred more frequently in patients receiving baricitinib compared with placebo in clinical trials [<a href="#rid71">71-73</a>].</p><p class="headingAnchor" id="H2521348276"><span class="h3">Tofacitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> inhibits JAK1, JAK2, and JAK 3 to disrupt cytokine and growth factor signaling, thereby reducing lymphocyte activation, differentiation, and function [<a href="#rid68">68</a>].</p><p>Infections reported in patients treated with <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> include pneumonia, cellulitis, herpes zoster, and urinary tract infections [<a href="#rid74">74-76</a>]. Other common infections include upper respiratory tract infections [<a href="#rid68">68,78</a>]. Opportunistic infections have been reported, including <em>M. tuberculosis</em>, <em>P. jirovecii</em> pneumonia, and cryptococcosis, as well as the reactivation of other viruses. Patients with HBV and HCV were excluded from clinical trials, but HBV reactivation has been observed [<a href="#rid79">79</a>]. It is unclear if risk of TB reactivation is lower with JAK inhibitors compared with tumor necrosis factor (TNF)-alpha inhibitor or other biologic agents.</p><p>Decreased responses to pneumococcal immunization, especially in combination with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, have been observed [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H199284886"><span class="h1">INTERLEUKIN-1 INHIBITORS</span><span class="headingEndMark"> — </span>Interleukin (IL)-1 inhibitors prevent the activation of potent proinflammatory cytokine cascades. (See  <a class="medical medical_review" href="/z/d/html/127997.html" rel="external">"Interleukin 1 inhibitors: Biology, principles of use, and adverse events"</a>.)</p><p class="headingAnchor" id="H3302637333"><span class="h2">Class-wide risk assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Treatment with IL-1 inhibitors predisposes individuals to the following infections  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes zoster virus</p><p class="bulletIndent2"><span class="glyph">•</span>Candidal infections</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection</p><p class="bulletIndent2"><span class="glyph">•</span>Aspergillosis</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis)</p><p></p><p>Since risk of infections with IL-1 inhibitors seems to be lower than with some other biologic agents (eg, tumor necrosis factor-alpha inhibitors [TNFi]), these agents can be a useful treatment option for patients who are undergoing evaluation for occult infections but would benefit from starting a biologic agent earlier than the time frame in which the evaluation for infection can be completed. Nevertheless, IL-1 inhibitors should not be initiated in patients with known active infections and should be held in the context of active infections that arise during treatment. IL-1 inhibitors should not be used in combination with TNFi [<a href="#rid83">83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test patients initiating IL-1 inhibitors for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting IL-1 inhibitors, as discussed above  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H3186461700"><span class="h2">Drug-specific risks</span></p><p class="headingAnchor" id="H1434777270"><span class="h3">Anakinra</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a> is an IL-1 receptor antagonist that prevents IL-1 from binding to IL-1 receptors [<a href="#rid84">84</a>]. IL-1 has a multitude of signaling responsibilities in the cell, and blocking this leads to reduced proinflammatory cytokine cascades.</p><p>The most commonly observed infections among patients treated with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> include upper respiratory tract infections, cellulitis, nasopharyngitis, and bone and joint infections [<a href="#rid84">84-86</a>]. Additional opportunistic infections reported in postmarketing studies include fungal, mycobacterial, and bacterial infections. Reactivation of <em>M. tuberculosis </em>infection has been reported but appears infrequent when appropriate testing and treatment are implemented [<a href="#rid86">86</a>]. The risk for HBV reactivation in patients receiving anakinra has not been studied.</p><p class="headingAnchor" id="H2407409857"><span class="h3">Canakinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a> is a humanized monoclonal antibody (mAb) directed against IL-1 beta. Canakinumab specifically binds to IL-1 beta and inhibits its downstream effector functions by blocking its ability to bind to IL-1 receptors [<a href="#rid87">87</a>]. This signal inhibition decreases the proinflammatory immune response.</p><p>The most common infections seen in patients on <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> include nasopharyngitis, upper respiratory tract infections, and influenza [<a href="#rid88">88-90</a>]. Opportunistic infections with aspergillosis, mycobacterial infections, herpes zoster, and cytomegalovirus (CMV) have been reported. Patients with TBI, HBV, and HCV were excluded from all canakinumab trials, and the risk for reactivation of chronic bacterial and viral infections is unclear [<a href="#rid89">89,90</a>].</p><p class="headingAnchor" id="H3773949886"><span class="h3">Rilonacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">Rilonacept</a> is a bispecific humanized mAb directed against IL-1 beta to limit IL-1 signaling and reduce inflammatory responses [<a href="#rid91">91,92</a>].</p><p>Upper respiratory tract infection is the most common infection in patients undergoing treatment. However, many other serious infections can occur due to the consequences of preventing the IL-1 signaling pathways, such as <em>M. tuberculosis</em> infection [<a href="#rid91">91-93</a>]. Injection site reactions are common and should be monitored for infection.</p><p class="headingAnchor" id="H2545319930"><span class="h1">INTERLEUKIN-4 INHIBITORS (DUPILUMAB)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> is a humanized monoclonal antibody (mAb) directed against interleukin (IL)-4 receptor subunit alpha. Dupilumab inhibits the downstream signaling of both IL-4 and IL-13, critical drivers of the type II inflammatory response [<a href="#rid94">94,95</a>]. Studies are ongoing to determine the safety of long-term usage [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'</a> and  <a class="medical medical_review" href="/z/d/html/114004.html" rel="external">"Evaluation and management of severe refractory atopic dermatitis (eczema) in adults", section on 'Dupilumab'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for infection</strong> – Generally, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> is associated with less infectious risk compared with other immunomodulators, such as <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid97">97</a>]  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>). Serious infections leading to drug discontinuation are infrequent, but patients should be monitored closely [<a href="#rid98">98</a>]. Herpes simplex virus infections have been reported in patients undergoing therapy with dupilumab. Most conjunctivitis seen in patients taking dupilumab is noninfectious, although bacterial and viral conjunctivitis can rarely occur [<a href="#rid97">97</a>]. Infection severity due to SARS-CoV-2 does not appear to be increased [<a href="#rid99">99-101</a>].</p><p></p><p class="bulletIndent1">The impact of <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> on infections due to helminths and chronic infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV are unknown, as patients with these conditions were excluded from clinical trials [<a href="#rid95">95</a>]. However, subsequent case reports of patients with chronic HBV and HCV treated with dupilumab have been reassuring [<a href="#rid102">102,103</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – Testing for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a>) can be decided on a case-by-case basis, based on the patient's risk factors and prior testing history for each of these infections, since there are no data indicating increased risk of reactivation with TBI and HBV in patients taking <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>) [<a href="#rid102">102-104</a>]. Since dupilumab selectively suppresses Th2 immune responses, it is unlikely to cause reactivation of HBV, HCV, or tuberculosis (TB). In a case series of five patients with atopic dermatitis and positive hepatitis B surface antigen who were treated with dupilumab, there were no cases of hepatitis B reactivation after two years of treatment [<a href="#rid102">102</a>]. (See <a class="local">'Pretreatment infectious testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – No vaccinations are necessary prior to initiating <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>).</p><p></p><p class="headingAnchor" id="H2819299071"><span class="h1">INTERLEUKIN-5 AND IMMUNOGLOBULIN E INHIBITORS</span><span class="headingEndMark"> — </span>Eosinophil and mast cell activation are critical aspects of the immune response to allergens and parasitic pathogens, causing inflammation and tissue damage. Interleukin (IL)-5, secreted by Th2 cells and mast cells, is a critical regulator of eosinophil differentiation, stimulation, and survival; activation and signaling occur upon IL-5-specific binding to its receptor (IL-5R). Monoclonal antibodies (mAbs) designed to inhibit this interaction by binding circulating IL-5 (<a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>) or competitively binding to IL-5R (<a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>) have been shown to deplete blood and tissue eosinophil counts [<a href="#rid105">105-107</a>]. <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> is a competitive inhibitor of immunoglobulin E (IgE), leading to inhibition of mast cell activation and release of inflammatory proteins [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Persistently uncontrolled asthma'</a>.)</p><p class="headingAnchor" id="H1542021227"><span class="h2">Class-wide risk assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Due to the known effect of IL-5 and IgE signaling on helminth clearance, there is a theoretical increased risk for parasitic infections  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>). Thus, in a patient presenting with signs and symptoms of infection, we consider the possibility and evaluate for parasitic infections, especially within an appropriate clinical context. If a parasitic infection is discovered following the start of therapy, treatment should be stopped until the infection is resolved.</p><p></p><p class="bulletIndent1">Due to the theoretical increased risk for parasitic infections, the major clinical trials for <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a> [<a href="#rid70">70,107,109-112</a>], <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> [<a href="#rid106">106,113-119</a>], <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a> [<a href="#rid105">105,120-122</a>], and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid123">123-128</a>] excluded patients with active parasitic infections and we do not know how much of an increased risk to parasitic infections these drugs confer. In a small randomized, double-blinded study of 137 participants in Brazil who were at high risk for helminth infection, there was a statistically nonsignificant trend toward higher incidence of parasitic infection in those who received omalizumab compared with placebo (50 versus 41 percent, OR 1.47, 95% CI 0.74-2.95) [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – For patients at increased risk for parasitic infections (eg, patients who live in or recently traveled from endemic countries), we test for possible quiescent parasitic infections with a <em>Strongyloides</em> spp immunoglobulin G (IgG) antibody and stool microscopy for ova, cysts, and helminths prior to initiation of these agents  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>). If any parasitic infections are found, they should be treated prior to the initiation of IL-5 inhibitor or anti-IgE monoclonal antibody agents. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Screening'</a> and  <a class="medical medical_review" href="/z/d/html/14001.html" rel="external">"Approach to stool microscopy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the herpes zoster vaccine to patients (especially those above the age of 50) starting <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, given the increased risk for herpes zoster infections  (<a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a>).</p><p></p><p class="headingAnchor" id="H4285195834"><span class="h2">Drug-specific risks</span></p><p class="headingAnchor" id="H2479792093"><span class="h3">Benralizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">Benralizumab</a> is a humanized cytolytic IgG1 mAb directed against the IL-5R alpha subunit. Due to a direct apoptotic effect on eosinophils via antibody-mediated cellular cytotoxicity [<a href="#rid130">130</a>], benralizumab results in greater depletion of circulating and tissue-resident eosinophils compared with drugs that bind IL-5 directly [<a href="#rid131">131</a>]. In a review of the Vigibase database, parasitic infections were more prevalent in patients taking benralizumab (0.23 percent) compared with <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> (0.07 percent), <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> (0.06 percent), <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> (0.04 percent), or placebo (0.02 percent) [<a href="#rid132">132</a>]. However, in most clinical trials, infections occurred at a similar rate in the benralizumab and placebo arms [<a href="#rid70">70,107,109-112</a>].</p><p class="headingAnchor" id="H2167893183"><span class="h3">Mepolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> is a humanized IgG1 kappa mAb directed against IL-5. The overall incidence of infections was similar in clinical trials of patients receiving mepolizumab compared with placebo [<a href="#rid106">106,113-116,118,119</a>]. However, multiple studies report cases of herpes zoster in patients taking mepolizumab [<a href="#rid106">106,113,114</a>]. Based on a small number of case studies, there is no clear evidence of increased COVID-19 severity in patients taking mepolizumab [<a href="#rid133">133,134</a>]. Nonetheless, the risk of hospitalization may be elevated in patients infected with SARS-CoV-2 [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H2060588803"><span class="h3">Reslizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">Reslizumab</a> is a humanized IgG4 kappa mAb directed against IL-5. The incidence of infections in clinical trials was similar among patients receiving reslizumab and placebo [<a href="#rid105">105,120-122</a>].</p><p class="headingAnchor" id="H2065444091"><span class="h3">Omalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> is a humanized IgG1 mAb that targets circulating IgE. Most studies have demonstrated a similar incidence of infections in patients receiving omalizumab compared with placebo [<a href="#rid123">123-128</a>]. A few case studies suggest that omalizumab does not increase the risk for SARS-CoV-2 infection or the development of severe COVID-19 [<a href="#rid136">136</a>]. In a randomized controlled trial exploring the rate of helminth infection in patients receiving omalizumab, there was a small increase in the incidence of helminth infections but no apparent difference in the severity of infection [<a href="#rid129">129</a>]. Omalizumab has also been associated with adverse effects that mimic infections, such as fever, arthralgias, and urticaria [<a href="#rid22">22,137</a>]. These symptoms have been reported in some individuals even after a year into the course of therapy [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1734280300"><span class="h1">OTHER INTERLEUKIN INHIBITORS (IL-6, IL-12, IL-17, IL-23)</span><span class="headingEndMark"> — </span>Interleukin (IL)-6, IL-12, IL-17, and IL-23 are all cytokines involved in inflammatory and immune response pathways. The discussed monoclonal antibodies (mAbs) are directed against these cytokines and interfere with downstream signaling processes, preventing the release of proinflammatory cytokines. These cytokines are produced in a vast array of cells, including those involved in T cell activation and stimulation of hematopoietic precursor cell proliferation and differentiation. The cytokines can also be found locally at sites of infection and inflammation. Continual production of these cytokines is involved in the pathogenesis of some autoimmune diseases, and targeting these cytokines through neutralization or antagonization is an effective strategy to treat these diseases [<a href="#rid138">138</a>]. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Biologic cytokine inhibitors'</a>.)</p><p class="headingAnchor" id="H358786531"><span class="h2">Sarilumab and tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">Sarilumab</a> and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> bind to soluble and membrane-bound IL-6 receptors and interfere with IL-6 signaling via the receptor [<a href="#rid139">139,140</a>]  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'IL-6 inhibition'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Patients treated with IL-6 inhibitors are at increased risk of the following infections:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) and hepatitis C virus (HCV)</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes zoster virus [<a href="#rid141">141</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Candidal infections</p><p class="bulletIndent2"><span class="glyph">•</span><em>Pneumocystis</em> pneumonia</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis) [<a href="#rid142">142,143</a>]</p><p></p><p>Long-term studies suggest that risk for infections is similar to other biologic agents, including tumor necrosis factor (TNF)-alpha inhibitors [<a href="#rid144">144-148</a>]. However, many of the opportunistic bacterial, viral, and fungal infections often occur during coadministration with other immunosuppressive medications [<a href="#rid149">149,150</a>]. Patients with HBV and HCV were excluded from trials using <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">sarilumab</a> and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>; however, reactivation of HBV has been reported [<a href="#rid151">151</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – For patients starting IL-6 inhibitors, we test for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting IL-6 inhibitors, as discussed above  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H1182480594"><span class="h2">Ixekizumab, secukinumab, brodalumab, and bimekizumab</span><span class="headingEndMark"> — </span>These mAbs are directed against IL-17. In particular, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> selectively bind IL-17A and inhibit its ability to interact with the IL-17 receptor [<a href="#rid15">15,16</a>]. <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">Brodalumab</a> binds IL-17RA and prevents its interactions with other IL-17-related proteins [<a href="#rid17">17</a>]. These actions prevent cytokine signaling and the subsequent release of proinflammatory cytokines. <a class="drug drug_general" data-topicid="138686" href="/z/d/drug information/138686.html" rel="external">Bimekizumab</a> is not available in the United States. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'IL-17 inhibition'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infections</strong> – Patients treated with IL-17 inhibitors are at increased risk of the following infections  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TB and other mycobacterial infections [<a href="#rid15">15-20</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Candidal infections, especially oral candidiasis [<a href="#rid18">18</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Dermatologic fungal infections (eg, tinea)</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial pathogens (eg, nasopharyngitis, upper respiratory tract infections, urinary tract infections) [<a href="#rid19">19,20</a>]</p><p></p><p>Based on case reports, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> has been used in patients with HBV and HCV infection without viral reactivation [<a href="#rid152">152</a>]. Very few cases of TB and other mycobacterial infections have been reported with these agents, and the overall risk is likely very low [<a href="#rid153">153</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – For patients initiating IL-17 inhibitors, we test for TBI  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>) prior to initiating treatment  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting IL-17 inhibitors, as discussed above  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H14348781"><span class="h2">Guselkumab, ustekinumab, and others</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">Guselkumab</a> is a mAb directed against IL-23 to prevent binding to its receptor, which inhibits downstream signaling to dampen proinflammatory cytokine responses [<a href="#rid154">154</a>]. <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> is a mAb directed against IL-12 and IL-23, interfering with natural killer cell activation and CD4+ T cell differentiation [<a href="#rid155">155</a>]. <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">Risankizumab</a> and <a class="drug drug_general" data-topicid="143211" href="/z/d/drug information/143211.html" rel="external">mirikizumab</a> are other IL-23 inhibitors with similar mechanism of action to guselkumab. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'IL-12/23 blockade'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for infections</strong> – Patients treated with IL-23 inhibitors are at increased risk of candidal and dermatologic fungal infections (eg, tinea)  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>).</p><p></p><p>Although the drug labels for these agents warns that the risk of TBI and HBV reactivation may be increased, postmarketing data have not shown a significantly increased risk of infection with these agents [<a href="#rid153">153,156</a>]. Nevertheless, we continue to test for these infections, because the benefit of testing outweighs the harms.</p><p><a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">Risankizumab</a> (an IL-23 inhibitor) appears to have a lower risk for HBV and HCV reactivation compared with <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> or <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test for TBI  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a>) in patients initiating <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> or <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). Since there are no reports of HBV or HCV reactivation in patients taking isankizumab, we do not test patients starting isankizumab for HBV or HCV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting IL-23 inhibitors, as discussed above  (<a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H645166815"><span class="h1">INTEGRIN INHIBITORS</span></p><p class="headingAnchor" id="H698665837"><span class="h2">Vedolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> is a monoclonal antibody (mAb) that binds alpha 4 beta 7 integrin and prevents its interaction with MAdCAM-1, which hinders the migration of memory T cells into the gastrointestinal tract [<a href="#rid157">157</a>]. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Vedolizumab'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – In clinical trials and postmarketing studies, infection rates were not significantly higher in patients receiving <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> compared with placebo [<a href="#rid157">157-161</a>]. However, certain serious infections have been <strong>rarely</strong> reported in those taking vedolizumab, including [<a href="#rid71">71</a>]  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Cytomegalovirus (CMV) disease (eg, colitis) and Epstein-Barr virus </p><p class="bulletIndent2"><span class="glyph">•</span>Progressive multifocal leukoencephalopathy (PML)</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial pathogens (eg, nasopharyngitis, sinopulmonary infections, gastroenteritis, perirectal abscesses) [<a href="#rid162">162,163</a>]</p><p></p><p><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> does not seem to affect the incidence of complications due to SARS-CoV-2 infection [<a href="#rid164">164</a>].</p><p><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> treatment should not be started in patients with severe infections nor be administered concomitantly with <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> or tumor necrosis factor (TNF)-alpha inhibitors due to additive infection risk [<a href="#rid14">14</a>].</p><p><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> appears to carry a low risk for opportunistic infections. In a pooled analysis of six trials that included 2830 patients, there was no increased risk of serious infection associated with vedolizumab exposure compared with placebo [<a href="#rid157">157</a>]. Both TB and CMV infections were reported in 1 person per 1000 person-years in the vedolizumab group.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – Prior to administering <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, we test for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), as the benefits of TBI preemptive treatment in those who test positive outweigh the risks associated with testing  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) for patients starting <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, as discussed above  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>) (see <a class="local">'Timing of vaccinations'</a> above). Administration of live vaccines before initiating vedolizumab is preferred. Live vaccines can be administered during therapy if the benefit outweighs the risk [<a href="#rid14">14</a>]. Vedolizumab does not appear to reduce parenterally delivered vaccine responses, but the response to oral vaccines may be lower [<a href="#rid165">165,166</a>].</p><p></p><p class="headingAnchor" id="H2670279804"><span class="h2">Natalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> is a selective adhesion molecule inhibitor, functioning as a humanized mAb that binds to alpha 4 beta 1 integrins on nonneutrophil leukocytes. This prevents alpha 4 beta 1 from interacting with vascular cell adhesion molecule 1 (VCAM-1) found in blood vessel lumens. By blocking the interaction of alpha 4 beta 1 to VCAM-1, leukocyte migration across the blood-brain barrier and interactions with extracellular matrix proteins are inhibited [<a href="#rid167">167,168</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for infections</strong> – Patients treated with <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> are at increased risk of the following infections  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TB [<a href="#rid169">169</a>] and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span><strong>PML and John Cunningham virus (JCV; can occur in both seropositive and seronegative patients)</strong> [<a href="#rid167">167,169,170</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Herpes simplex virus meningoencephalitis [<a href="#rid169">169</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Varicella zoster virus (VZV) and other herpesviruses (eg, acute retinal necrosis) [<a href="#rid171">171,172</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus (HBV) and hepatitis C virus (HCV) [<a href="#rid173">173</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Aspergillosis [<a href="#rid169">169</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection [<a href="#rid169">169</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (nasopharyngitis, upper respiratory tract infections, urinary tract infections) [<a href="#rid169">169,174,175</a>]</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> should not be administered to patients with severe infections nor in combination with other immunomodulatory therapies. Corticosteroids should be discontinued prior to natalizumab initiation. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis", section on 'Natalizumab'</a>.)</p><p></p><p>In a nationwide Swedish cohort of 1573 patients taking <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, the risk of developing a serious infection within the first six years of treatment was 11.4 per 1000 person-years (95% CI 8.3-15.3) compared with the general population [<a href="#rid170">170</a>]. Although the risk is elevated, it was still lower than the infection risk associated with use of <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in this study. (See <a class="local">'Sphingosine-1-phosphate receptor modulators (fingolimod)'</a> below and <a class="local">'Rituximab'</a> above.)</p><p>Although rare, PML is a significant concern in patients taking <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> due to its high mortality rate and moderate to severe disability among survivors. The risk of natalizumab-associated PML for an individual patient varies according to JCV antibody status, prior immunosuppressant treatment, and the duration of natalizumab exposure  (<a class="graphic graphic_table graphicRef55637" href="/z/d/graphic/55637.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/z/d/html/1697.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Treatment and prognosis", section on 'Morbidity and mortality'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – We test for TBI  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), HBV  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), HCV  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a>), and JCV prior to starting <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>) [<a href="#rid169">169,176,177</a>]. We also obtain baseline brain magnetic resonance imaging (MRI) prior to initiating therapy, continue to monitor JCV antibodies every six months, and repeat the brain MRI annually during therapy. If JCV antibody is positive at any time, some experts opt to not initiate or discontinue natalizumab due to the increased risk of PML incidence [<a href="#rid167">167,169,170,178</a>]. As an example, in a multinational observational study of over 6500 patients started on natalizumab, 44 (0.7 percent) developed PML over the five-year follow-up period [<a href="#rid178">178</a>]. Half of these patients had positive JCV antibodies recorded in the previous six months, while another 47 percent did not have JCV antibody results recorded.</p><p></p><p class="bulletIndent1">Surveillance for PML in patients with a positive JCV antibody who remain on <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis", section on 'Surveillance for PML'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and varicella/herpes zoster vaccines) in patients starting <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, as discussed above  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>). (See <a class="local">'Timing of vaccinations'</a> above.) Live vaccines should be avoided during the treatment period and for four months following the cessation of therapy [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H3122794067"><span class="h2">Others</span><span class="headingEndMark"> — </span>Etrolizumab is similar to <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> in mechanism of action and increased susceptibility to infections (see <a class="local">'Vedolizumab'</a> above). Efalizumab is similar to <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a> and also increases the risk of PML. It is no longer available in the United States or Canada due to fatal PML infections [<a href="#rid179">179</a>].</p><p class="headingAnchor" id="H2899775435"><span class="h1">SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS (FINGOLIMOD)</span><span class="headingEndMark"> — </span>Drugs belonging to the sphingosine-1-phosphate (S1P) modulators class include <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>. All of them have similar risk of infection; patients taking S1P receptor modulators other than fingolimod should be managed similar to patients taking fingolimod. (See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Sphingosine 1-phosphate (S1P) receptor modulators'</a> and  <a class="medical medical_review" href="/z/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis", section on 'S1PR modulators'</a>.)</p><p><a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> binds to S1P receptors, downregulating S1P signaling to inhibit the exit of naive T cells and central memory T cells from lymph nodes [<a href="#rid180">180,181</a>]. Expression of cytokines on CD4+ T cells is also inhibited [<a href="#rid181">181,182</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Patients taking <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> are at increased risk for the following infections [<a href="#rid183">183,184</a>]  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculosis (TB) and other mycobacterial infections </p><p class="bulletIndent2"><span class="glyph">•</span>Varicella zoster virus (VZV) and herpes simplex virus infections</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive multifocal leukoencephalopathy (PML)</p><p class="bulletIndent2"><span class="glyph">•</span>Human herpesvirus-8-associated tumors </p><p class="bulletIndent2"><span class="glyph">•</span>Cryptococcal infection</p><p class="bulletIndent2"><span class="glyph">•</span>Common viral and bacterial infections (sinopulmonary infections, pneumonia, urinary tract infections, cellulitis)</p><p></p><p>A significant increase in risk for lower respiratory tract infections and herpesvirus infections was identified in clinical trials, with two fatal cases of disseminated VZV reported [<a href="#rid185">185-188</a>]. Patients should be carefully monitored during treatment for lower respiratory infections and herpesvirus infections [<a href="#rid189">189,190</a>].</p><p>Although risk of PML with <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> is lower than with <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, cases of PML have been reported [<a href="#rid191">191,192</a>]. No fingolimod dose-dependent increase in infection risk has been noted [<a href="#rid181">181</a>]. Fingolimod should not be used with natalizumab due to increased risk of PML. (See <a class="local">'Natalizumab'</a> above and  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – For patients starting S1P receptor modulators, we test for tuberculosis infection (TBI)  (<a class="graphic graphic_algorithm graphicRef116497" href="/z/d/graphic/116497.html" rel="external">algorithm 1</a>), hepatitis B virus (HBV)  (<a class="graphic graphic_algorithm graphicRef129226" href="/z/d/graphic/129226.html" rel="external">algorithm 3</a>), and hepatitis C virus (HCV)  (<a class="graphic graphic_algorithm graphicRef127067" href="/z/d/graphic/127067.html" rel="external">algorithm 4</a> and <a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>). We prefer to test for John Cunningham virus (JCV), similar to the approach used in patients receiving <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, due to the increased risk for PML in patients receiving <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> [<a href="#rid193">193</a>]. However, testing for JCV is not routine among all clinicians, and no guidelines are available to guide testing. Fingolimod should be held if any signs or symptoms of PML develop while further work-up is pursued [<a href="#rid193">193</a>]. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis", section on 'Surveillance for PML'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – We administer the routine and additional vaccinations (pneumococcal and herpes zoster vaccines) for patients starting S1P receptor modulators, as discussed above  (<a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>). (See <a class="local">'Timing of vaccinations'</a> above.)</p><p></p><p class="headingAnchor" id="H1968397176"><span class="h1">COMPLEMENT PATHWAY INHIBITORS (ECULIZUMAB)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">Eculizumab</a> is a monoclonal antibody (mAb) directed against protein C5 of the membrane attack complex (MAC). The binding of eculizumab to C5 reduces the number of terminal complement components (C5b-9) that form the MAC, thereby decreasing the cytolysis of targeted encapsulated bacteria [<a href="#rid194">194-196</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of infection</strong> – Patients treated with <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> are at increased risk for  (<a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serious infections due to encapsulated bacteria (eg, <em>Neisseria meningitidis,</em> <em>S. pneumoniae</em>, and <em>Haemophilus influenzae</em> type b (Hib) [<a href="#rid194">194,197</a>]), particularly severe or fatal meningococcal infections [<a href="#rid194">194,195</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Common bacterial and viral infections (eg, upper respiratory infections, urinary tract infections) [<a href="#rid197">197</a>]</p><p></p><p>The severity of SARS-CoV-2 infection does not appear to be higher in patients treated with <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> [<a href="#rid198">198</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment infectious testing</strong> – No testing is necessary for patients prior to starting <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a>  (<a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – Due to the high risk of bacterial infections, initial or booster vaccinations for <em>N. meningitidis</em> (both for ACWY serogroups and serogroup B) and <em>S. pneumoniae</em> are recommended <strong>at least </strong>two weeks before the start of treatment or as soon as possible  (<a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a>). Children receiving <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> treatment may be at particularly increased risk for infection with <em>S. pneumoniae</em> or Hib, and age-appropriate vaccinations should be administered according to standard guidelines. (See  <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection"</a> and  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Immunization of persons at increased risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other considerations</strong> – Antibacterial prophylaxis with penicillin, or a macrolide if penicillin allergic, can be considered while receiving this treatment, but the risks and benefits are not well evaluated [<a href="#rid197">197</a>]. This is discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'</a>.)</p><p></p><p>Close monitoring for serious infections is warranted in all patients receiving <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> since infection is still possible (although less likely) in a patient who has been vaccinated and/or is receiving antimicrobial prophylaxis [<a href="#rid195">195</a>].</p><p class="headingAnchor" id="H1738047419"><span class="h1">MONOCLONAL ANTIBODIES WITH NO KNOWN EFFECT ON THE IMMUNE SYSTEM</span><span class="headingEndMark"> — </span>Certain monoclonal antibodies (mAbs) are designed to not affect the immune system and thus do not predispose the patients taking these agents to infections. Agents in this category include <a class="drug drug_general" data-topicid="103780" href="/z/d/drug information/103780.html" rel="external">evolocumab</a>, abciximab, and calcitonin gene-related peptide antagonists (eg, <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">erenumab</a>, <a class="drug drug_general" data-topicid="119169" href="/z/d/drug information/119169.html" rel="external">galcanezumab</a>, <a class="drug drug_general" data-topicid="133172" href="/z/d/drug information/133172.html" rel="external">atogepant</a>).</p><p class="headingAnchor" id="H2733570066"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic mechanisms</strong> – Biologic agents are designed to interfere with the biological activity of a component of the immune system, typically a cytokine or a cellular receptor. By interfering with the normal activities of these molecules, biologic agents disrupt signaling pathways that drive activation and migration of immune cells to sites of infection, thereby interfering with the host immune response and increasing risk for infection. (See <a class="local">'Immunologic mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment testing for infections</strong> – Baseline testing for some latent infections is recommended prior to initiating therapy with many of the medications in this section  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>). In general, most of the biologic agents discussed here warrant testing for tuberculosis infection (TBI), hepatitis B virus (HBV), and hepatitis C virus (HCV). If any infections are discovered on pretreatment testing, we treat the underlying infection and hold off on starting the biologic agent until the infection is controlled. Close monitoring is paramount to make sure there is no worsening of the underlying infection once the biologic agent is started. (See <a class="local">'Pretreatment infectious testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment vaccinations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We administer age-appropriate routine vaccinations (including SARS-CoV-2 vaccine series and annual influenza vaccination) to all patients starting biologic agents or a janus kinase (JAK) inhibitor prior to initiation of therapy when feasible, because vaccination may be less effective during and after therapy or may be contraindicated (eg, live vaccines)  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For some drugs, pneumococcal and herpes zoster virus vaccines should also be administered prior to initiation of biologic agent, if possible  (<a class="graphic graphic_table graphicRef143349" href="/z/d/graphic/143349.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef143348" href="/z/d/graphic/143348.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef143347" href="/z/d/graphic/143347.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef143346" href="/z/d/graphic/143346.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef143343" href="/z/d/graphic/143343.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef143345" href="/z/d/graphic/143345.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live vaccines should generally be avoided during treatment with immunomodulatory agents. (See <a class="local">'Prior to initiating biologics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of vaccines during treatment</strong> – Vaccination with nonlive vaccines during therapy may be considered if the benefit of vaccination outweighs the risk. When possible, vaccination should be given at the nadir of immunosuppression. (See <a class="local">'During treatment with biologics'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 2014; 58:1649.</a></li><li><a class="nounderline abstract_t">Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf 2015; 14:571.</a></li><li><a class="nounderline abstract_t">Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011; 38:1258.</a></li><li><a class="nounderline abstract_t">Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8:443.</a></li><li><a class="nounderline abstract_t">Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807.</a></li><li><a class="nounderline abstract_t">Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 2022; 4:e177.</a></li><li><a class="nounderline abstract_t">van Kempen ZLE, Wieske L, Stalman EW, et al. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? Mult Scler Relat Disord 2022; 57:103416.</a></li><li><a class="nounderline abstract_t">Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 2021; 3:e778.</a></li><li><a class="nounderline abstract_t">Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) 2023; 75:449.</a></li><li><a class="nounderline abstract_t">Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2017; 76:1559.</a></li><li><a class="nounderline abstract_t">Schwob JM, Samer CF, Lalive PH, Eperon GA. Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit-risk assessment for natalizumab. J Travel Med 2021; 28.</a></li><li><a class="nounderline abstract_t">Tashtoush B, Okafor NC, Ramirez JF, Smolley L. Follicular Bronchiolitis: A Literature Review. J Clin Diagn Res 2015; 9:OE01.</a></li><li><a class="nounderline abstract_t">Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66:1384.</a></li><li class="breakAll">Takeda Pharmaceuticals. Entyvio. Highlights of Prescribing Information 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. Secukinumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. Ixekizumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. Brodalumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75:83.</a></li><li><a class="nounderline abstract_t">Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017; 389:2317.</a></li><li><a class="nounderline abstract_t">Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181.</a></li><li><a class="nounderline abstract_t">Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.</a></li><li class="breakAll">Food and Drug Administration. Omalizumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152:1297.</a></li><li><a class="nounderline abstract_t">Cowley NJ, Owen A, Shiels SC, et al. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial. JAMA Intern Med 2017; 177:774.</a></li><li><a class="nounderline abstract_t">Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57:1431.</a></li><li><a class="nounderline abstract_t">Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64:1265.</a></li><li><a class="nounderline abstract_t">Talotta R, Atzeni F, Sarzi Puttini P. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. BMC Pharmacol Toxicol 2016; 17:17.</a></li><li><a class="nounderline abstract_t">Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012; 56:1420.</a></li><li><a class="nounderline abstract_t">Fanouriakis A, Vassilopoulos D, Repa A, et al. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) 2014; 53:195.</a></li><li><a class="nounderline abstract_t">Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013; 40:787.</a></li><li><a class="nounderline abstract_t">Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol 2016; 68:56.</a></li><li><a class="nounderline abstract_t">Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67:547.</a></li><li><a class="nounderline abstract_t">Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58:79.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013; 22:144.</a></li><li><a class="nounderline abstract_t">Chen DR, Cohen PL. Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumtol 2012; 7:159.</a></li><li><a class="nounderline abstract_t">Lanini S, Molloy AC, Prentice AG, et al. Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study. BMC Infect Dis 2013; 13:317.</a></li><li><a class="nounderline abstract_t">Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One 2014; 9:e87379.</a></li><li><a class="nounderline abstract_t">Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779.</a></li><li><a class="nounderline abstract_t">Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094.</a></li><li><a class="nounderline abstract_t">Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377:1331.</a></li><li><a class="nounderline abstract_t">Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.</a></li><li><a class="nounderline abstract_t">Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis 2018; 5:ofy174.</a></li><li><a class="nounderline abstract_t">Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83:673.</a></li><li><a class="nounderline abstract_t">Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology 2021; 97:e1870.</a></li><li><a class="nounderline abstract_t">Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol 2022; 4:e33.</a></li><li><a class="nounderline abstract_t">Hughes R, Whitley L, Fitovski K, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 2021; 49:102725.</a></li><li><a class="nounderline abstract_t">Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456.</a></li><li><a class="nounderline abstract_t">Seery N, Sharmin S, Li V, et al. Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. CNS Drugs 2021; 35:907.</a></li><li><a class="nounderline abstract_t">Brunnberg U, Hentrich M, Hoffmann C, et al. HIV-Associated Malignant Lymphoma. Oncol Res Treat 2017; 40:82.</a></li><li><a class="nounderline abstract_t">Aksoy S, Dizdar O, Hayran M, Harputluoğlu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009; 50:357.</a></li><li><a class="nounderline abstract_t">Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21:628.</a></li><li><a class="nounderline abstract_t">Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10:89.</a></li><li><a class="nounderline abstract_t">van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol 2015; 42:1761.</a></li><li><a class="nounderline abstract_t">Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24 Suppl 2:S71.</a></li><li><a class="nounderline abstract_t">Kapoor T, Mahadeshwar P, Hui-Yuen J, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Sci Med 2020; 7.</a></li><li><a class="nounderline abstract_t">van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75.</a></li><li><a class="nounderline abstract_t">Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 2017; 19:101.</a></li><li><a class="nounderline abstract_t">Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128:1295.</a></li><li><a class="nounderline abstract_t">Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2016; 9:44.</a></li><li><a class="nounderline abstract_t">Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018; 11:1756286418773025.</a></li><li><a class="nounderline abstract_t">Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 2021; 78:736.</a></li><li><a class="nounderline abstract_t">Zhang B. Ofatumumab. MAbs 2009; 1:326.</a></li><li><a class="nounderline abstract_t">Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18:263.</a></li><li><a class="nounderline abstract_t">Ugarte-Gil MF, Alarcón GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis 2022; 81:970.</a></li><li><a class="nounderline abstract_t">Fabris M, De Marchi G, Domenis R, et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun 2022; 129:102827.</a></li><li><a class="nounderline abstract_t">O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72 Suppl 2:ii111.</a></li><li class="breakAll">Food and Drug Administration. Tofacitinib Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128.</a></li><li><a class="nounderline abstract_t">Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 2017; 376:652.</a></li><li><a class="nounderline abstract_t">Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017; 76:88.</a></li><li><a class="nounderline abstract_t">Genovese MC, Kremer J, Zamani O, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med 2016; 374:1243.</a></li><li><a class="nounderline abstract_t">Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75:1843.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol 2017; 69:1969.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol 2017; 69:1960.</a></li><li><a class="nounderline abstract_t">Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia 2014; 28:1750.</a></li><li><a class="nounderline abstract_t">Iwamoto N, Tsuji S, Takatani A, et al. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One 2017; 12:e0177057.</a></li><li><a class="nounderline abstract_t">Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 2018; 77:780.</a></li><li><a class="nounderline abstract_t">Kusne Y, Kimes KE, Feller FF, et al. Coccidioidomycosis in Patients Treated With Ruxolitinib. Open Forum Infect Dis 2020; 7:ofaa167.</a></li><li><a class="nounderline abstract_t">Kubo S, Nakayamada S, Sakata K, et al. Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Front Immunol 2018; 9:1510.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016; 75:687.</a></li><li><a class="nounderline abstract_t">Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412.</a></li><li class="breakAll">Food and Drug Administration. Anakinra Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36:1118.</a></li><li><a class="nounderline abstract_t">Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1006.</a></li><li class="breakAll">Food and Drug Administration. Canakinumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Lachmann HJ, Lauwerys B, Miettunen P, et al. Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clin Exp Rheumatol 2021; 39 Suppl 132:51.</a></li><li><a class="nounderline abstract_t">Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416.</a></li><li><a class="nounderline abstract_t">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119.</a></li><li><a class="nounderline abstract_t">Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res 2010; 3:1.</a></li><li><a class="nounderline abstract_t">Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443.</a></li><li class="breakAll">Food and Drug Administration. Rilonacept Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019; 15:2129.</a></li><li class="breakAll">Food and Drug Administration. Dupilumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022; 23:365.</a></li><li><a class="nounderline abstract_t">Schneeweiss MC, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. J Am Acad Dermatol 2021; 84:300.</a></li><li><a class="nounderline abstract_t">Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335.</a></li><li><a class="nounderline abstract_t">Patruno C, Stingeni L, Fabbrocini G, et al. Dupilumab and COVID-19: What should we expect? Dermatol Ther 2020; 33:e13502.</a></li><li><a class="nounderline abstract_t">El-Qushayri AE, Mahmoud MA, Salman S, et al. Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients. Dermatol Ther 2022; 35:e15476.</a></li><li><a class="nounderline abstract_t">Ungar B, Glickman JW, Golant AK, et al. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. J Allergy Clin Immunol Pract 2022; 10:134.</a></li><li><a class="nounderline abstract_t">Matsutani M, Imai Y, Nakatani-Kusakabe M, et al. Dupilumab in atopic dermatitis patients with chronic hepatitis B. Journal of Cutaneous Immunology and Allergy 2021; 5:65.</a></li><li><a class="nounderline abstract_t">Mota F. Atopic Dermatitis Patient With Hepatitis C Treated With Dupilumab-A Case Report. Actas Dermosifiliogr 2023.</a></li><li><a class="nounderline abstract_t">Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 2023; 37:1135.</a></li><li><a class="nounderline abstract_t">Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355.</a></li><li><a class="nounderline abstract_t">Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651.</a></li><li><a class="nounderline abstract_t">Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2017; 5:568.</a></li><li><a class="nounderline abstract_t">Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. J Immunol Res 2016; 2016:8163803.</a></li><li><a class="nounderline abstract_t">Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388:2115.</a></li><li><a class="nounderline abstract_t">Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019; 7:46.</a></li><li><a class="nounderline abstract_t">Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med 2021; 9:260.</a></li><li><a class="nounderline abstract_t">Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376:2448.</a></li><li><a class="nounderline abstract_t">Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973.</a></li><li><a class="nounderline abstract_t">Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198.</a></li><li><a class="nounderline abstract_t">Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189.</a></li><li><a class="nounderline abstract_t">Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022; 400:502.</a></li><li><a class="nounderline abstract_t">Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med 2017; 377:1613.</a></li><li><a class="nounderline abstract_t">Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5:390.</a></li><li><a class="nounderline abstract_t">Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1141.</a></li><li><a class="nounderline abstract_t">Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest 2016; 150:789.</a></li><li><a class="nounderline abstract_t">Corren J, Weinstein S, Janka L, et al. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest 2016; 150:799.</a></li><li><a class="nounderline abstract_t">Murphy K, Jacobs J, Bjermer L, et al. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract 2017; 5:1572.</a></li><li><a class="nounderline abstract_t">Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184.</a></li><li><a class="nounderline abstract_t">Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005.</a></li><li><a class="nounderline abstract_t">Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924.</a></li><li><a class="nounderline abstract_t">Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254.</a></li><li><a class="nounderline abstract_t">Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36.</a></li><li><a class="nounderline abstract_t">Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632.</a></li><li><a class="nounderline abstract_t">Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007; 37:197.</a></li><li><a class="nounderline abstract_t">Wu Y, Li JJ, Kim HJ, et al. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity. AAPS J 2015; 17:1417.</a></li><li><a class="nounderline abstract_t">Ghassemian A, Park JJ, Tsoulis MW, Kim H. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts. Allergy Asthma Clin Immunol 2021; 17:3.</a></li><li><a class="nounderline abstract_t">Lifar P, Montastruc F, Reber LL, et al. Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study. Am J Respir Crit Care Med 2023; 207:1253.</a></li><li><a class="nounderline abstract_t">Licari A, Castagnoli R, Votto M, et al. Biologic Use in Allergic and Asthmatic Children and Adolescents During the COVID-19 Pandemic. Pediatr Allergy Immunol Pulmonol 2020; 33:155.</a></li><li><a class="nounderline abstract_t">Aksu K, Yesilkaya S, Topel M, et al. COVID-19 in a patient with severe asthma using mepolizumab. Allergy Asthma Proc 2021; 42:e55.</a></li><li><a class="nounderline abstract_t">Papaioannou AI, Fouka E, Tzanakis N, et al. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics. J Allergy Clin Immunol Pract 2022; 10:2588.</a></li><li><a class="nounderline abstract_t">Passante M, Napolitano M, Dastoli S, et al. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Dermatol Ther 2021; 34:e15111.</a></li><li class="breakAll">Xolair. https://www.xolairhcp.com/?adobe_mc=MCMID%3D25061105514458683721135041519440244321%7CMCORGID%3DDF784CF658BD66380A495D3E%2540AdobeOrg%7CTS%3D1685127355 (Accessed on May 29, 2023).</li><li><a class="nounderline abstract_t">Lai Y, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol 2016; 28:181.</a></li><li class="breakAll">Food and Drug Administration. Sarilumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. Tocilizumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 20, 2023).</li><li><a class="nounderline abstract_t">Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford) 2020; 59:292.</a></li><li><a class="nounderline abstract_t">Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019; 58:849.</a></li><li><a class="nounderline abstract_t">Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford) 2017; 56:1746.</a></li><li><a class="nounderline abstract_t">De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.</a></li><li><a class="nounderline abstract_t">Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014; 73:69.</a></li><li><a class="nounderline abstract_t">Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13:R141.</a></li><li><a class="nounderline abstract_t">Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377:317.</a></li><li><a class="nounderline abstract_t">Lauper K, Kearsley-Fleet L, Galloway JB, et al. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter? Rheumatology (Oxford) 2023.</a></li><li><a class="nounderline abstract_t">Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol 2015; 67:1424.</a></li><li><a class="nounderline abstract_t">Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73:1626.</a></li><li><a class="nounderline abstract_t">Katelani S, Fragoulis GE, Bakasis AD, et al. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatology (Oxford) 2023; 62:SI252.</a></li><li><a class="nounderline abstract_t">Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol 2018; 32:e120.</a></li><li><a class="nounderline abstract_t">Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol 2021; 35:824.</a></li><li class="breakAll">Food and Drug Administration. Guselkumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li class="breakAll">Food and Drug Administration. Stelara (Ustekinumab) Injection, for Subcutaneous or Intravenous. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168:844.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66:839.</a></li><li><a class="nounderline abstract_t">Feagan BG, Bhayat F, Khalid M, et al. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. J Crohns Colitis 2018; 12:905.</a></li><li><a class="nounderline abstract_t">Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711.</a></li><li><a class="nounderline abstract_t">Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147:618.</a></li><li><a class="nounderline abstract_t">Cohen RD, Bhayat F, Blake A, Travis S. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis 2020; 14:192.</a></li><li><a class="nounderline abstract_t">Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52:1353.</a></li><li><a class="nounderline abstract_t">Agrawal M, Zhang X, Brenner EJ, et al. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. J Crohns Colitis 2021; 15:1877.</a></li><li><a class="nounderline abstract_t">Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015; 64:77.</a></li><li><a class="nounderline abstract_t">Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol 2022; 7:342.</a></li><li><a class="nounderline abstract_t">Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 2007; 3:259.</a></li><li><a class="nounderline abstract_t">Yaldizli O, Putzki N. Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2009; 2:115.</a></li><li><a class="nounderline abstract_t">Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord 2017; 10:327.</a></li><li><a class="nounderline abstract_t">Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2020; 77:184.</a></li><li><a class="nounderline abstract_t">Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013; 57:849.</a></li><li><a class="nounderline abstract_t">Sood AB, Kumar G, Robinson J. Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab. J Ophthalmic Inflamm Infect 2016; 6:26.</a></li><li><a class="nounderline abstract_t">Hillen ME, Cook SD, Samanta A, et al. Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e72.</a></li><li><a class="nounderline abstract_t">Shirani A, Stüve O. Natalizumab: Perspectives from the Bench to Bedside. Cold Spring Harb Perspect Med 2018; 8.</a></li><li><a class="nounderline abstract_t">Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018; 17:405.</a></li><li><a class="nounderline abstract_t">Benkert TF, Dietz L, Hartmann EM, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One 2012; 7:e52208.</a></li><li><a class="nounderline abstract_t">Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870.</a></li><li><a class="nounderline abstract_t">Foley J, Carrillo-Infante C, Smith J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord 2020; 39:101863.</a></li><li><a class="nounderline abstract_t">Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35.</a></li><li><a class="nounderline abstract_t">Ingwersen J, Aktas O, Kuery P, et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2012; 142:15.</a></li><li><a class="nounderline abstract_t">Zhao Z, Ma CL, Gu ZC, et al. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials. Front Immunol 2021; 12:611711.</a></li><li><a class="nounderline abstract_t">Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33:91.</a></li><li><a class="nounderline abstract_t">Grebenciucova E, Reder AT, Bernard JT. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord 2016; 9:158.</a></li><li><a class="nounderline abstract_t">Samudralwar RD, Spec A, Cross AH. Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease. Int J MS Care 2019; 21:275.</a></li><li><a class="nounderline abstract_t">Grebenciucova E, Pruitt A. Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2017; 17:88.</a></li><li><a class="nounderline abstract_t">Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402.</a></li><li><a class="nounderline abstract_t">Winkelmann A, Loebermann M, Reisinger EC, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12:217.</a></li><li><a class="nounderline abstract_t">Issa NP, Hentati A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 2015; 84:99.</a></li><li><a class="nounderline abstract_t">Fazekas F, Berger T, Fabjan TH, et al. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr 2012; 162:354.</a></li><li><a class="nounderline abstract_t">Signoriello E, Bonavita S, Sinisi L, et al. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. Mult Scler Relat Disord 2020; 40:101963.</a></li><li><a class="nounderline abstract_t">Gyang TV, Hamel J, Goodman AD, et al. Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 2016; 86:1843.</a></li><li><a class="nounderline abstract_t">Faulkner M. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf 2015; 14:1737.</a></li><li><a class="nounderline abstract_t">McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87:117.</a></li><li><a class="nounderline abstract_t">McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:734.</a></li><li><a class="nounderline abstract_t">Parikh SR, Lucidarme J, Bingham C, et al. Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169.</a></li><li class="breakAll">Food and Drug Administration. Eculizumab Highlights of Prescribing Information. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Mastellos DC, Pires da Silva BGP, Fonseca BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020; 220:108598.</a></li></ol></div><div id="topicVersionRevision">Topic 127104 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647016" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25630559" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infection risk associated with anti-TNF-αagents: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498482" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24613021" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16947384" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34977602" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34847379" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396154" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36597813" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28468794" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33367888" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit-risk assessment for natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26500941" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Follicular Bronchiolitis: A Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284544" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284544" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284544" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284544" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284544" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27180926" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28551073" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455412" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473917" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473917" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28219691" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437539" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050184" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22392695" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27098382" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22127282" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771951" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18203761" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588946" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315675" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921185" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439931" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23213069" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22792128" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849292" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24498318" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047971" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003886" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976863" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264918" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30094293" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528824" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34610987" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34806036" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482590" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : COVID-19 in ocrelizumab-treated people with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054760" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tolerability and safety of rituximab (MabThera).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33847902" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28253516" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : HIV-Associated Malignant Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19263297" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845637" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656128" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26276965" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29447988" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32513809" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039396" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521808" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908031" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of rituximab on human in vivo antibody immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26788130" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774057" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ocrelizumab: a new milestone in multiple sclerosis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724354" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20068404" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ofatumumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914324" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : BAFF, APRIL and their receptors: structure, function and signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35172961" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427999" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532440" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Janus kinase inhibitors in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532440" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Janus kinase inhibitors in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532440" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Janus kinase inhibitors in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609406" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Benralizumab, an anti-interleukin-5 receptorαmonoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199814" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27689735" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028914" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Baricitinib in Patients with Refractory Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113415" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845577" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845604" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24625550" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Disseminated tuberculosis associated with ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28472115" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28663308" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548203" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Coccidioidomycosis in Patients Treated With Ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30002661" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795907" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146410" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146410" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447938" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Anakinra for rheumatoid arthritis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396977" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety of extended treatment with anakinra in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396977" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Safety of extended treatment with anakinra in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34622762" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494217" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Use of canakinumab in the cryopyrin-associated periodic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845751" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096352" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668535" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668535" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785362" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A review of dupilumab in the treatment of atopic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785362" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A review of dupilumab in the treatment of atopic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35567671" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33038471" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27690741" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32362061" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Dupilumab and COVID-19: What should we expect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35357060" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34737108" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Dupilumab in atopic dermatitis patients with chronic hepatitis B</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37290670" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Atopic Dermatitis Patient With Hepatitis C Treated With Dupilumab-A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36695072" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Expert consensus on the systemic treatment of atopic dermatitis in special populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25736990" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901886" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28545978" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097159" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609408" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-actingβ2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30416083" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33357499" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28530840" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264686" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Mepolizumab and exacerbations of refractory eosinophilic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199059" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Mepolizumab treatment in patients with severe eosinophilic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199060" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35964610" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893134" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395936" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872587" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056586" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018175" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122156" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496232" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410369" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432142" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529281" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483846" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15080818" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17250692" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26205082" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33407869" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36883943" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: A VigiBase Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35922025" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Biologic Use in Allergic and Asthmatic Children and Adolescents During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33536114" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : COVID-19 in a patient with severe asthma using mepolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35752436" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34427028" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34427028" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545932" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545932" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545932" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31312844" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590833" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28957557" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252525" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904473" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21884601" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Integrated safety in tocilizumab clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745999" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Trial of Tocilizumab in Giant-Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37758229" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733246" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297381" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Sarilumab, a fully human monoclonal antibody against IL-6Rαin patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37871924" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28960490" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Safety of secukinumab in hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790003" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790003" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790003" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23301632" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893500" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : The safety of vedolizumab for ulcerative colitis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788248" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964932" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Vedolizumab as induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964933" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Vedolizumab as induction and maintenance therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859203" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504340" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876349" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Long-term safety of vedolizumab for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33884425" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763133" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123676" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360634" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Natalizumab: A new treatment for relapsing remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21180646" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Natalizumab in the treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28861122" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31589278" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728144" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27439780" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25815364" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29500304" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Natalizumab: Perspectives from the Bench to Bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545067" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284936" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591293" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Risk of natalizumab-associated progressive multifocal leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901758" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19719397" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21669553" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33763062" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061941" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27645366" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31889932" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940162" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089954" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26943779" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Disease-modifying therapies and infectious risks in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416038" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : VZV encephalitis that developed in an immunized patient during fingolimod therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895849" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31986424" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164718" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Fingolimod-associated PML in a patient with prior immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26394704" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492930" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28704351" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864711" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738544" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738544" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32961333" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
